{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:52:53Z","timestamp":1761511973062,"version":"3.40.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology"],"published-print":{"date-parts":[[2004]]},"abstract":"<jats:p>Several neurotransmitter mechanisms have been proposed to play a role in the actions of morphine. We reported that centrally administered endothelin A (ET&lt;sub&gt;A&lt;\/sub&gt;) receptor antagonists potentiate morphine analgesia in rats. It has also been reported that ET&lt;sub&gt;B&lt;\/sub&gt; agonist, IRL1620, has antinociceptive action mediated through opiate receptors in the periphery. The present study was conducted to determine if central ET&lt;sub&gt;B&lt;\/sub&gt; receptors are involved in analgesic actions of morphine. The effect of intracerebroventricular (i.c.v.) administration of ET&lt;sub&gt;B&lt;\/sub&gt; receptor agonist, IRL1620, on morphine-induced analgesia and hyperthermia was determined in the rat. Morphine (4 mg\/kg, s.c.) produced a significant increase (84%) in tail-flick latency compared to the control group and the analgesic response lasted for 4 h. IRL1620 (30 \u00b5g, i.c.v.) did not produce any increase (16%) in tail-flick latency over the 5-hour observation period in vehicle-treated rats. Pretreatment with IRL1620 (3, 10, and 30 \u00b5g, i.c.v.) did not have any significant effect on the intensity and duration of morphine (4 mg\/kg, s.c.)-induced analgesia. Morphine (4 mg\/kg, s.c.) administration produced an increase in body temperature compared to the control group. In vehicle-pretreated rats, IRL1620 (30 \u00b5g, i.c.v.) did not produce any change in body temperature. The morphine-induced hyperthermic effect was not altered in IRL1620-pretreated rats. These studies demonstrate that IRL1620, a specific ET&lt;sub&gt;B&lt;\/sub&gt; receptor agonist, did not affect the morphine-induced analgesic and hyperthermic effect in rats. It can be concluded that central ET&lt;sub&gt;B&lt;\/sub&gt; receptors are not involved in modulation of pharmacological actions of morphine.<\/jats:p>","DOI":"10.1159\/000078628","type":"journal-article","created":{"date-parts":[[2004,8,9]],"date-time":"2004-08-09T09:38:42Z","timestamp":1092044322000},"page":"20-25","source":"Crossref","is-referenced-by-count":7,"title":["Central Endothelin-B Receptor Stimulation Does Not Affect Morphine Analgesia in Rats"],"prefix":"10.1159","volume":"72","author":[{"given":"Shaifali","family":"Bhalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Matwyshyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2004,8,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(92)90300-E"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-9781(97)00009-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/348732a0"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/348730a0"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.176"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nm885"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/0168-0102(89)90047-3"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(89)90610-1"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0143-4179(90)90062-4"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(88)90025-1"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90284-D"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(98)00281-7"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00865-1"}],"container-title":["Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/78628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/78628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:16:17Z","timestamp":1745464577000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000078628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004]]},"references-count":13,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2004,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000078628","archive":["Portico"],"relation":{},"ISSN":["0031-7012","1423-0313"],"issn-type":[{"type":"print","value":"0031-7012"},{"type":"electronic","value":"1423-0313"}],"subject":[],"published":{"date-parts":[[2004]]}}}